Kim Dongchan, Gupta Bhavya, Wong Geoffrey Yuet Mun
School of Medicine, Western Sydney University, Sydney, New South Wales 2560, Australia.
Department of Upper Gastrointestinal Surgery, Royal North Shore Hospital, Sydney, New South Wales 2065, Australia.
Comput Struct Biotechnol J. 2023 Mar 11;21:2129-2136. doi: 10.1016/j.csbj.2023.03.011. eCollection 2023.
The liver is the most common site of metastasis in colorectal cancer. Multimodal treatment, including liver resection, is potentially curative and prolongs survival for selected patients with colorectal liver metastases (CRLM). However, the treatment of CRLM remains challenging because recurrence is common, and prognosis varies widely between patients despite curative-intent treatment. Clinicopathological features and tissue-based molecular biomarkers, either alone or in combination, are insufficient for accurate prognostication. As most of the functional information in cells resides in the proteome, circulating proteomic biomarkers may be useful for rationalising the molecular complexities of CRLM and identifying potentially prognostic molecular subtypes. High-throughput proteomics has accelerated a range of applications including protein profiling of liquid biopsies for biomarker discovery. Moreover, these proteomic biomarkers may provide non-invasive prognostic information even before CRLM resection. This review evaluates recently discovered circulating proteomic biomarkers in CRLM. We also highlight some of the challenges and opportunities with translating these discoveries into clinical applications.
肝脏是结直肠癌最常见的转移部位。多模式治疗，包括肝切除术，对部分结直肠癌肝转移（CRLM）患者可能具有治愈性并能延长生存期。然而，CRLM的治疗仍然具有挑战性，因为复发很常见，而且尽管进行了根治性治疗，患者的预后差异仍然很大。临床病理特征和基于组织的分子生物标志物，单独或联合使用，都不足以进行准确的预后评估。由于细胞中的大多数功能信息存在于蛋白质组中，循环蛋白质组生物标志物可能有助于梳理CRLM的分子复杂性并识别潜在的预后分子亚型。高通量蛋白质组学加速了一系列应用，包括用于生物标志物发现的液体活检蛋白质谱分析。此外，这些蛋白质组生物标志物甚至在CRLM切除前就可能提供非侵入性的预后信息。本综述评估了最近在CRLM中发现的循环蛋白质组生物标志物。我们还强调了将这些发现转化为临床应用所面临的一些挑战和机遇。
